Tuesday, the South Carolina Statehouse discussed everything from bathroom bills to ivermectin. Here's how things progressed.

In the latest trading session, Moderna (MRNA) closed at $43.00, marking a +2.8% move from the previous day. The stock's change was more than the S&P 500's daily loss of 2.06%. On the other hand, the ...

Moderna and Merck shared five-year study data showing their combined cancer treatment cut the risk of melanoma coming back or ...

Intismeran autogene with pembrolizumab shows a 49% reduction in recurrence or death risk in high-risk resected melanoma ...

Moderna and Merck said on Tuesday their experimental personalized vaccine continued to cut the risk of death or recurrence of ...

A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.

Patients with severe melanoma who received the treatment were 49% less likely to die or have their cancer return, ...

There's a potential new method to treat infertility through mRNA technology, according to Johns Hopkins Medicine research.

Gaithersburg’s Novavax has struck a deal to give Pfizer the rights to its adjuvant technology — for a potential $530 million ...

Saturated fat is back, according to the new dietary guidelines that reflect the Make America Healthy Again agenda. Doctors ...

The Nanoparticle Contract Manufacturing market offers opportunities in pharmaceuticals, biotech, and advanced materials, ...

The experimental mRNA-based drug sharply reduced the risk of recurrence or death when combined with immunotherapy Keytruda, ...